Sarah Ketterer's NVO Position Overview
Sarah Ketterer (via Causeway Capital Management LLC) currently holds 993,850 shares of Novo Nordisk A/S (NVO) worth $50.57 M, representing 0.70% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.
Based on 13F filings, Sarah Ketterer has maintained this position in NVO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 342,095 shares.
Analysis based on 13F filings available since 2013 Q2
Sarah Ketterer's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Sarah Ketterer
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +297,871 | Add 42.80% | 993,850 | $50.88 |
| Q3 2025 | +342,095 | Add 96.67% | 695,979 | $55.49 |
| Q2 2025 | +353,884 | New Buy | 353,884 | $69.02 |
Sarah Ketterer's Novo Nordisk A/S Investment FAQs
Sarah Ketterer first purchased Novo Nordisk A/S (NVO) in Q2 2025, acquiring 353,884 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer has held Novo Nordisk A/S (NVO) for 3 quarters since Q2 2025.
Sarah Ketterer's largest addition to Novo Nordisk A/S (NVO) was in Q2 2025, adding 353,884 shares worth $24.43 M.
According to the latest 13F filing for Q4 2025, Sarah Ketterer's firm, Causeway Capital Management LLC, owns 993,850 shares of Novo Nordisk A/S (NVO), valued at approximately $50.57 M.
As of the Q4 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.70% of Sarah Ketterer's publicly disclosed stock portfolio, making it one of their key holdings.
Sarah Ketterer's peak holding in Novo Nordisk A/S (NVO) was 993,850 shares, as reported at the end of Q4 2025.